Condition
Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory clinical trials and research
As of November 12, 2026, Find a Trial lists 3 Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory clinical trials that are recruiting, at sites in 15 countries (most in Austria (3), Belgium (3), Denmark (3)). By phase: Phase 1/2 (3). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 3Clinical trials
- 15Countries
Newest Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Dasatinib and venetoclax with dexamethasone, cyclophosphamide, and cytarabine for children and young adults with relapsed or refractory ALL/LBL with MAPK/SRC changes | Phase 1/2 | Vienna and 32 other locations | Recruiting | Mar 2, 2023 |
| Ruxolitinib and venetoclax added to chemotherapy for children and young adults with relapsed or refractory ALL/LBL | Phase 1/2 | Vienna and 32 other locations | Recruiting | Feb 27, 2023 |
| Combination treatment for children with relapsed or refractory blood cancers | Phase 1/2 | Vienna and 35 other locations | Recruiting | Dec 21, 2022 |
All recruiting trials (3)
-
Dasatinib and venetoclax with dexamethasone, cyclophosphamide, and cytarabine for children and young adults with relapsed or refractory ALL/LBL with MAPK/SRC changes
This treatment tests whether adding dasatinib and venetoclax to dexamethasone, cyclophosphamide, and cytarabine helps children and young people (up to 21) whose relapsed or refractory acute lymphoblastic leukemia or lymphoblastic lymphoma have specific MAPK/SRC pathway changes.
-
Ruxolitinib and venetoclax added to chemotherapy for children and young adults with relapsed or refractory ALL/LBL
This trial tests whether adding ruxolitinib and venetoclax to dexamethasone, cyclophosphamide and cytarabine helps children and young adults with relapsed or refractory acute lymphoblastic leukemia or lymphoblastic lymphoma who have IL7R/JAK-STAT pathway changes.
-
Combination treatment for children with relapsed or refractory blood cancers
This study is testing a new combination of medications to see if it can help children and young adults with tough-to-treat blood cancers feel better and improve their chances of recovery.
Related topics
Quick answers
How many Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory clinical trials are recruiting right now?
3, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 15 countries. The most sites are in Austria (3 trials), Belgium (3 trials), Denmark (3 trials), Finland (3 trials), France (3 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 3. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.